Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial
Nature Medicine, Published online: 01 September 2026; doi:10.1038/s41591-026-04565-6 The phase 3 NSABP B-59/GeparDouze trial, in which patients with early-stage triple-negative breast cancer received neoadjuvant chemotherapy with or without atezolizumab, did not meet its primary endpoint of event-free survival, and comprehensive translational analyses show tumor microenvironment-dependent…
We haven't written up this one. Nature Medicine has the full story — the link below goes straight to it.
